Xilio Therapeutics, Inc. Common Stock (XLO) Stock Price

XLOStock

$9.08−6.61%52W

Market Cap$59.75M

P/E—

PEG Ratio—

Div yield—

Beta-0.11

XLO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)3.77%

Price vs S&P 500 (4W)-2.61%

VGM Score72.63

Book Value / Share (Quarterly)$12.55

P/TBV (Annual)0.31x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-9.92

Price vs S&P 500 (YTD)-9.39%

Net Profit Margin (TTM)-58.52%

EPS (TTM)$-3.51

10-Day Avg Trading Volume0.01M

EPS Excl Extra (TTM)$-3.51

EPS (Annual)$-4.19

ROI (Annual)-99.33%

Cash / Share (Quarterly)$26.00

Revenue Growth QoQ (YoY)331.67%

ROA (Last FY)-22.65%

Revenue Growth TTM (YoY)476.71%

EBITD / Share (TTM)$-3.68

ROE (5Y Avg)-152.43%

Operating Margin (TTM)-78.98%

Cash Flow / Share (Annual)$-1.22

P/B Ratio0.75x

P/B Ratio (Quarterly)0.67x

Net Income / Employee (Annual)$-461,000

EV / Revenue (TTM)-1.80x

Net Interest Coverage (TTM)-581.41x

ROA (TTM)-21.38%

EPS Incl Extra (Annual)$-4.19

Current Ratio (Annual)2.58x

Quick Ratio (Quarterly)3.50x

3-Month Avg Trading Volume0.04M

52-Week Price Return-6.61%

Revenue / Employee (TTM)$703,700

Tangible BV / Share (Quarterly)$1.91

P/S Ratio (Annual)1.24x

Asset Turnover (Annual)0.28x

52-Week High$12.74

EPS Excl Extra (Annual)$-4.19

CapEx CAGR (5Y)-25.05%

26-Week Price Return15.02%

Quick Ratio (Annual)2.53x

13-Week Price Return7.17%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.59x

Enterprise Value$-96.19M

Asset Turnover (TTM)0.37x

Revenue / Employee (Annual)$575,900

Pretax Margin (Annual)-80.05%

Cash / Share (Annual)$30.36

3-Month Return Std Dev35.18%

Net Income / Employee (TTM)$-411,800

ROE (Last FY)-99.33%

Net Interest Coverage (Annual)-1.08x

EPS Basic Excl Extra (Annual)$-4.19

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-3.51

ROI (TTM)-39.20%

P/S Ratio (TTM)1.01x

Revenue / Share (Annual)$5.24

Tangible BV / Share (Annual)$3.85

Price vs S&P 500 (52W)-24.92%

Year-to-Date Return2.57%

5-Day Price Return-3.26%

EPS Normalized (Annual)$-4.19

ROA (5Y Avg)-65.62%

Net Profit Margin (Annual)-80.05%

Month-to-Date Return0.88%

Cash Flow / Share (TTM)$-2.89

EBITD / Share (Annual)$-4.84

Operating Margin (Annual)-95.92%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-147.11%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-3.51

P/TBV (Quarterly)0.62x

P/B Ratio (Annual)0.95x

Pretax Margin (TTM)-58.52%

Book Value / Share (Annual)$7.79

Price vs S&P 500 (13W)4.38%

Beta-0.11x

Revenue / Share (TTM)$3.27

ROE (TTM)-39.20%

52-Week Low$6.47

gGradeA

mGradeC

vgmGradeB

XLO Earnings Surprise History

Q2 25-2.24est. -1.12

Q3 25-1.54est. -0.42

Q2 26-0.33est. -0.59

XLO Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.20

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
XLOXilio Therapeutics, Inc. Common Stock	—	A	C	$9.08
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Xilio Therapeutics, Inc. Common Stock

Xilio Therapeutics is a clinical-stage biotechnology company developing tumor-activated immunotherapy treatments designed to improve cancer outcomes while minimizing systemic side effects. The company's proprietary platform generates novel I-O molecules that localize anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, and immune cell engagers. This approach aims to optimize therapeutic efficacy while reducing the toxicity associated with conventional immunotherapies.